OPKO Health (OPK) to Release Quarterly Earnings on Thursday

OPKO Health (NASDAQ:OPK) is expected to be releasing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect OPKO Health to post earnings of ($0.07) per share and revenue of $139.7570 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.15 on Wednesday. OPKO Health has a 12-month low of $1.11 and a 12-month high of $2.04. The company has a current ratio of 3.70, a quick ratio of 3.32 and a debt-to-equity ratio of 0.25. The firm’s 50 day moving average is $1.28 and its 200 day moving average is $1.36. The stock has a market capitalization of $882.86 million, a P/E ratio of -4.60 and a beta of 1.47.

Hedge Funds Weigh In On OPKO Health

Several hedge funds have recently modified their holdings of the stock. Zacks Investment Management bought a new position in shares of OPKO Health during the fourth quarter worth $27,000. StoneX Group Inc. purchased a new stake in OPKO Health in the 4th quarter worth $27,000. Cibc World Markets Corp bought a new position in shares of OPKO Health during the 4th quarter valued at about $34,000. EP Wealth Advisors LLC purchased a new position in shares of OPKO Health during the fourth quarter valued at about $37,000. Finally, Strs Ohio bought a new stake in shares of OPKO Health in the first quarter worth about $53,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analyst Ratings Changes

OPK has been the subject of several research analyst reports. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Thursday, October 30th. Jefferies Financial Group reissued a “hold” rating and issued a $1.60 target price (down from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. Wall Street Zen raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a report on Thursday, November 20th. They set a “neutral” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $2.28.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.